CoChat

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections

Open access
Shaw, Karen Joy, Ibrahim, Ashraf S. · 2020 · Journal of Fungi

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Abstract

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix demonstrates broad spectrum in vitro activity against yeasts and molds, including difficult to treat pathogens. Because of its novel mechanism of action, manogepix retains potency against many resistant strains including echinocandin-resistant Candida and azole-resistant Aspergillus. Manogepix is also active against pathogens that demonstrate intrinsic resistance to other drug classes, such as Scedosporium, Lomentospora prolificans, and Fusarium with variable activity against Mucorales. Fosmanogepix demonstrates significant in vivo efficacy in mouse and rabbit disseminated infection models due to C. albicans, C. glabrata, C. auris, C. tropicalis, Coccidioides immitis, and F. solani as well as pulmonary infection models of A. fumigatus, A. flavus, S.prolificans, S. apiospermum and Rhizopus arrhizus. Clinical trials demonstrated high oral bioavailability (>90%), enabling switching between fosmanogepix intravenous and oral formulations without compromising blood levels. Favorable drug-drug interaction, tolerability, and wide tissue distribution profiles are observed making fosmanogepix an attractive option for the treatment of invasive fungal infections. This systematic review summarizes the findings of published data on fosmanogepix.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jof6040239

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The structures of fosmanogepix and manogepix.
Figure 1 The structures of fosmanogepix and manogepix.CC BY · PubMed Central
Figure 2 The mechanism of action of manogepix. Modified from 2019 Covel et al. [26]. Gwt1 is an enzyme which catalyzes an acyl group transfer reaction, an essential part of the GPI biosynthesis pathway. This occurs in the lumen of the endoplasmic reticulum. Gwt1 catalyzes the inositol acylation of glucosaminyl phosphatidylinositol (GlcN-PI), resulting in the formation glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), an intermediate in the biosynthesis of GPI anchors.
Figure 2 The mechanism of action of manogepix. Modified from 2019 Covel et al. [26]. Gwt1 is an enzyme which catalyzes an acyl group transfer reaction, an essential part of the GPI biosynthesis pathway. This occurs in the lumen of the endoplasmic reticulum. Gwt1 catalyzes the inositol acylation of glucosaminyl phosphatidylinositol (GlcN-PI), resulting in the formation glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), an intermediate in the biosynthesis of GPI anchors.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 4

  1. Hata, K., Hori, T., Miyazaki, M., and Watanabe, N. (2011, January 17–20). In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, F1–1377. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
  2. Horii, T., Okubo, M., Miyazaki, M., Hata, K., and Watanabe, N.-A. (2010, January 12–15). In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. F1–843. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA.
  3. Petraitis, V., Petraitiene, R., Maung, B.B.W., Mansbach, R., Shaw, K.J., and Walsh, T.J. (2018, January 21–24). Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model. Proceedings of the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018), Madrid, Spain.
  4. Watanabe, N.-A., Horii, T., Miyazaki, M., and Hata, K. (2011, January 17). In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Proceedings of the F1–1378, in Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.

Cited by

Items 101–200 of 228

Metadata

Authors
Shaw, K. J., & Ibrahim, A. S.
Affiliations
  • Hearts Consulting Group, LLC, Poway, CA 92064, USA
  • University of California, Los Angeles (US)
Corresponding author
  • Shaw, Karen Joy
  • Ibrahim, Ashraf S.
Venue
Journal of Fungi
Publisher
MDPI AG
Published
2020-10-22
Volume
6
Issue
4
Pages
239
ISSN
2309-608X (ISSN-L)
OpenAlex
W3093555016
Cited by
229
References
64
Citations by year
2026: 43 · 2025: 47 · 2024: 36 · 2023: 47 · 2022: 30 · 2021: 25
FWCI
1.20
Type
journal article
Language
en
Open access
Locations
  • Journal of Fungi (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
National Institute of Allergy and Infectious Diseases (R01AI063503)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
fosmanogepix, manogepix, invasive fungal infections, antifungal drug development, Candida, Aspergillus, echinocandin resistance, azole resistance, Scedosporium, Lomentospora prolificans, Fusarium, Mucorales, oral bioavailability, drug-drug interactions, drug tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.